∗ abeomics

12-8074: Anti-Human IL 12/23 (Briakinumab) - PE

Clonality :	Monoclonal
Clone Name :	ABT-874
Application :	Functional Assay, FACS, IF
Reactivity :	Human
Alternative Name :	IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23
Isotype :	Human IgG1lambda
Immunogen Information : This antibody was produced by phage display technology.	

Description

Expression Host : HEK-293

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.

Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23alpha to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

Product Info

Amount :	50 μg
Content :	Concentration : 0.2 mg/ml This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage condition :	This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze.

Application Note

The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is $\leq 1.0 \text{ } \tilde{A} \square \hat{A} \mu g$ per 106 cells in a volume of 100 $\tilde{A} \square \hat{A} \mu l$. Titration of the reagent is recommended for optimal performance for each application.